WallStreetZenWallStreetZen

NASDAQ: ALDX
Aldeyra Therapeutics Inc Stock

$3.48+0.08 (+2.35%)
Updated Jun 21, 2024
ALDX Price
$3.48
Fair Value Price
$2.16
Market Cap
$206.76M
52 Week Low
$1.42
52 Week High
$8.54
P/E
-6.82x
P/B
1.82x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$30.01M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.25
Operating Cash Flow
-$31M
Beta
1.45
Next Earnings
Aug 1, 2024
Ex-Dividend
N/A
Next Dividend
N/A

ALDX Overview

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ALDX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ALDX ($3.48) is overvalued by 61.3% relative to our estimate of its Fair Value price of $2.16 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ALDX ($3.48) is not significantly undervalued (61.3%) relative to our estimate of its Fair Value price of $2.16 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ALDX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ALDX due diligence checks available for Premium users.

Be the first to know about important ALDX news, forecast changes, insider trades & much more!

ALDX News

Valuation

ALDX fair value

Fair Value of ALDX stock based on Discounted Cash Flow (DCF)
Price
$3.48
Fair Value
$2.16
Overvalued by
61.30%
ALDX ($3.48) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ALDX ($3.48) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ALDX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ALDX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-6.82x
Industry
-5.75x
Market
30.75x

ALDX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.82x
Industry
6.2x
ALDX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ALDX's financial health

Profit margin

Revenue
$0.0
Net Income
-$8.1M
Profit Margin
0%
ALDX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$141.3M
Liabilities
$27.9M
Debt to equity
0.25
ALDX's short-term assets ($140.85M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ALDX's short-term assets ($140.85M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ALDX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ALDX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$10.0M
Investing
-$30.4M
Financing
$18.2k
ALDX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ALDX vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ALDX$206.76M+2.50%-6.82x1.82x
CDXC$206.22M+0.74%-54.60x7.12x
CDXS$207.44M+4.63%-3.16x2.62x
STTK$207.80M+4.92%-2.26x1.61x
RANI$209.24M+3.75%-3.22x28.28x

Aldeyra Therapeutics Stock FAQ

What is Aldeyra Therapeutics's quote symbol?

(NASDAQ: ALDX) Aldeyra Therapeutics trades on the NASDAQ under the ticker symbol ALDX. Aldeyra Therapeutics stock quotes can also be displayed as NASDAQ: ALDX.

If you're new to stock investing, here's how to buy Aldeyra Therapeutics stock.

What is the 52 week high and low for Aldeyra Therapeutics (NASDAQ: ALDX)?

(NASDAQ: ALDX) Aldeyra Therapeutics's 52-week high was $8.54, and its 52-week low was $1.42. It is currently -59.25% from its 52-week high and 145.07% from its 52-week low.

How much is Aldeyra Therapeutics stock worth today?

(NASDAQ: ALDX) Aldeyra Therapeutics currently has 59,414,489 outstanding shares. With Aldeyra Therapeutics stock trading at $3.48 per share, the total value of Aldeyra Therapeutics stock (market capitalization) is $206.76M.

Aldeyra Therapeutics stock was originally listed at a price of $7.20 in May 2, 2014. If you had invested in Aldeyra Therapeutics stock at $7.20, your return over the last 10 years would have been -51.67%, for an annualized return of -7.01% (not including any dividends or dividend reinvestments).

How much is Aldeyra Therapeutics's stock price per share?

(NASDAQ: ALDX) Aldeyra Therapeutics stock price per share is $3.48 today (as of Jun 21, 2024).

What is Aldeyra Therapeutics's Market Cap?

(NASDAQ: ALDX) Aldeyra Therapeutics's market cap is $206.76M, as of Jun 24, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Aldeyra Therapeutics's market cap is calculated by multiplying ALDX's current stock price of $3.48 by ALDX's total outstanding shares of 59,414,489.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.